Navigation Links
ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
Date:1/30/2009

ATHENS, Ga., Jan. 30 /PRNewswire/ -- ArunA Biomedical, Inc., announced today that it will make its hN2(TM) cells commercially available to the research community in early 2009. The cells, derived from NIH registered human embryonic cell lines, are offered as a normal, consistent population of neural cells in an adherent monolayer format, a product never before offered to the research community. hN2 cells provide a human cell based format for research ranging from Alzheimer's to spinal cord injury and depression.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080819/CLTU003LOGO )

"ArunA has further developed its adherent monolayer technology by creating hN2(TM), a normal human neural cell ideal for drug screening, toxicology studies and basic neural research and we are pleased to be able to offer these cells commercially to the research market," says David Ray, ArunA's Chief Executive Officer. "By offering our products through multi-national distribution partners, we will provide broad access to the unique tools that may accelerate the pace of neural research with more physiologically relevant cellular research models," Ray said.

About ArunA Biomedical

Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human embryonic stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases. The company's first product, hNP1(TM) (ENSTem-A(TM)), is based on patented technology licensed from the University of Georgia. For more information, visit www.arunabiomedical.com.


'/>"/>
SOURCE ArunA Biomedical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
2. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
3. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
4. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
5. Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test
6. SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market
7. NCIIA Announces Launch of 4th Annual Student Biomedical Innovation Competition
8. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
9. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
10. Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
11. Environmental Tectonics Corporations BioMedical Division Announces New Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- GlobeImmune, Inc. today announced it has entered into a ... of its common stock to NantCell, Inc., a member ... sale of its common stock, NantCell has agreed to ... 200,000 shares, an estimated $2.0 million in value, of ... to enter into this strategic agreement with NantCell," said ...
(Date:3/23/2017)... York , March 23, 2017 According ... plasma products and derivatives market is fragmented due to the presence of ... such as Proliant, Thermo Fisher , and Sigma-Aldrich, compete with ... these three companies, collectively, held more than 76% of this market ... As ...
(Date:3/22/2017)... ... March 22, 2017 , ... Researchers face a ... lab samples to full-size tissues, bones, even whole organs to implant in people ... delivers blood deep into the developing tissue. , Current bioengineering techniques, including ...
(Date:3/22/2017)... 2017   iSpecimen ®, the marketplace ... Pathology Service (DPS), a full-service anatomic pathology reference ... United States , has joined a program offered ... (DHIN) to make human biospecimens and associated data ... program, announced in 2015 as a collaboration between iSpecimen ...
Breaking Biology Technology:
(Date:3/1/2017)... BEDFORD, Mass. , March 1, 2017  Aware, ... and services, announced that Richard P. Moberg ... Officer and co-President and Chief Financial Officer and Treasurer ... will continue to serve as a member of the ... T. Russell , Aware,s co-Chief Executive Officer and co-President, ...
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber Ventures ... it has led a $3.5 million investment in  Polarity ... Strategic Cyber Ventures is DC based and is led ... Hank Thomas . Ron Gula , also a ... also participated in this series A round of funding. ...
(Date:2/21/2017)... N.Y. and PORTLAND, Ore. ... ) and the Avamere Family of Companies (Avamere Health ... today announced a six-month research study that will apply ... improve eldercare at senior living and health centers. By ... Avamere hopes to gain insights into physical and environmental ...
Breaking Biology News(10 mins):